...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith share issue
Reply New Message
Prev Message Back To Forum Threaded View Next Message

fouremm, $3USD is the minimum for a NASDAQ listing, coincidence?? maybe for a NAsdaq IPO it does not matter as it would be priced higher than $3 anyways .  Would like to see an IPO but a  CVR or buyout would be preferred for just ZEN 3694 and than IPO the other molecule indications,  THE STAR FACTORY AS MENTIONED by SF

6 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply